AstraZeneca Names New CFO Amidst Falling Sales And Profits
AstraZeneca plc (NYSE:AZN)Â (LON:AZN) named a new chief financial officer amidst reporting a sharp fall in its third-quarter sales and profits.
Drug maker AstraZeneca plc (NYSE:AZN) (LON:AZN) reported earnings per share of $1.21, falling short of analysts’ estimates of $1.27.
Marc Dunoyer to replace Simon Lowth
Simon Lowth, AstraZeneca’s former CFO,
SORRY! This content is exclusively for paying members. If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.
